drugset / Trial / NCT00019656

Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer

NCT00019656

Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of perifosine in treating patients who have refractory solid tumors or hematologic cancer.

Timeline

Start
1999-08
Primary completion
Completion

Publications

  • Results Monga M, Messmann RA, Headlee D, et al.: A phase I trial of oral perifosine in patients with refractory neoplasms. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-1837, 7b, 2002.
  • Results Messmann RA, Headlee D, Woo EW, et al.: A phase I trial of oral perifosine with different loading and maintenance schedules in patients with refractory neoplasms. [Abstract] Proc Am Assoc Cancer Res 42: A-2880, 2001.

Drugs

EvaluationDrugModalityDoseRoute
Subject Perifosine Small molecule Oral